Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 19;39(9):e14908. doi: 10.1111/dme.14908

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

(a) Proportion of Patients with a HbA1c <59 mmol/mol by the percentage of total expenditure on biguanides. (b) Proportion of Patients with a HbA1c <59 mmol/mol by the percentage of total expenditure on sulphonylureas. (c) Proportion of Patients with a HbA1c <59 mmol/mol by the percentage of total expenditure on thiaglitazones. (d) Proportion of Patients with a HbA1c <59 mmol/mol by the percentage of total expenditure on DPPIV inhibitors. (e) Proportion of Patients with a HbA1c <59 mmol/mol by the percentage of total expenditure on SGLT2 inhibitors. (f) Proportion of Patients with a HbA1c <59 mmol/mol by the percentage of total expenditure on GLP‐1 agonists. (g) Proportion of Patients with a HbA1c <59 mmol/mol by the percentage of total expenditure on insulin